Updated Testing: Aminoglycoside-Induced Hearing Loss Panel (MT-RNR1 gene)
- Guideline driven:
- This panel includes 3 high risk variants in MT-RNR1 associated with aminoglycoside induced hearing loss according to the Clinical Pharmacogenetics Implementation Consortium (CPIC) (m.1095T>C, m.1494C>T, and m.1555A>G)
- Impact to clinical care:
- Aminoglycosides are widely used antibiotics known to have side effects including a risk of hearing loss. Individuals carrying one of three high risk variants in MT-RNR1 have an increased risk of aminoglycoside-induced hearing loss.
- CPIC guideline recommends individuals with the high-risk MT-RNR1 variants should “avoid aminoglycosides unless the high risk of permanent hearing loss is outweighed by the severity of infection and safe or effective alternative therapies are not available”.
- The MT-RNR1 gene, including the above risk variants, is included in our OtoSCOPE v9 panel
Methodology: Targeted Sanger sequencing of MT-RNR1 variants: m.1095T>C, m.1494C>T, and m.1555A>G
Turn around time: 3 weeks
Sample types accepted:
- 3-5cc EDTA whole blood
- 5 ug DNA, resuspended in at least 50 ul of DNA Elution Buffer
- Saliva (DNA Genotek, ORAGene Discover, OGR-500)
- Buccal swabs, at least 4 (DNA Genotek, OraCollect, OCD-100)
Contact MORL for any questions or concerns at MORL@uiowa.edu
Cost: $185
CPT: 81401
The Clinical Diagnostics Service of the Molecular Otolaryngology and Renal Research Laboratories is a Joint Commission-approved CLIA-accredited diagnostic laboratory.